Jill Gilbert

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister et al. · Journal of Clinical Oncology · 2017 · 652 citations

Medicine, Oncology, Pharmacology +17

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018

A. Dimitrios Colevas, Sue S. Yom, David G. Pfister et al. · Journal of the National Comprehensive Cancer Network · 2018 · 632 citations · Full text

Medicine, Oncology, Surgery +12

Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma

Paulo C. Rodrı́guez, Claudia Patricia Pardo Hernández, David Quiceno et al. · The Journal of Experimental Medicine · 2005 · 595 citations · Full text

Life Sciences, Immunology, Oncology +17

E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group

Shanthi Marur, Shuli Li, Anthony J. Cmelak et al. · Journal of Clinical Oncology · 2017 · 504 citations

Medicine, Oncology, Radiation Oncology +14

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017

David J. Adelstein, Maura L. Gillison, David G. Pfister et al. · Journal of the National Comprehensive Cancer Network · 2017 · 377 citations · Full text

Medicine, Oncology, Otolaryngology +12